Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

This collaborative meta-analysis of 28 published or unpublished RCTs, including 10,319 patients, shows that treatment with HCQ was associated with increased mortality in COVID-19 patients, and there was no benefit from treatment with CQ.

Substantial COVID-19 research investment has been allocated to randomized clinical trials
(RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or
early discontinuation. We aim to estimate the effects of hydroxychloroquine and chloroquine
on survival in COVID-19 from all currently available RCT evidence, published and unpublished.
We present a rapid meta-analysis of ongoing, completed, or discontinued RCTs on
hydroxychloroquine or chloroquine treatment for any COVID-19 patients (protocol: https:// We systematically identified unpublished RCTs (, WHO
International Clinical Trials Registry Platform, Cochrane COVID-registry up to June 11, 2020),
and published RCTs (PubMed, medRxiv and bioRxiv up to October 16, 2020). All-cause
mortality has been extracted (publications/preprints) or requested from investigators and
combined in random-effects meta-analyses, calculating odds ratios (ORs) with 95% confidence
intervals (CIs), separately for hydroxychloroquine and chloroquine. Prespecified
subgroup analyses include patient setting, diagnostic confirmation, control type, and publication
status. Sixty-three trials were potentially eligible. We included 14 unpublished trials
(1308 patients) and 14 publications/preprints (9011 patients). Results for hydroxychloroquine
are dominated by RECOVERY and WHO SOLIDARITY, two highly pragmatic trials, which
employed relatively high doses and included 4716 and 1853 patients, respectively (67% of
the total sample size). The combined OR on all-cause mortality for hydroxychloroquine is 1.11
(95% CI: 1.02, 1.20; I² = 0%; 26 trials; 10,012 patients) and for chloroquine 1.77 (95%CI: 0.15,
21.13, I² = 0%; 4 trials; 307 patients). We identified no subgroup effects. We found that
treatment with hydroxychloroquine is associated with increased mortality in COVID-19
patients, and there is no benefit of chloroquine. Findings have unclear generalizability to
outpatients, children, pregnant women, and people with comorbidities.

Completed your training?

Fill in the form and we’ll send you… in a few days!